Morgan Stanley sees Moderna’s phase 3 RSV vaccine data as catalyst-driven idea

Morgan Stanley analyst Matthew Harrison says the first interim analysis from Moderna’s (MRNA) Phase 3 RSV vaccine study expected in the near-term could drive the stock up by 5% or more if its efficacy and safety are in-between those of Pfizer (PFE) and GSK (GSK). The analyst’s base case of about 60% probability is that vaccine efficacy is between Pfizer/GSK and safety similar to Pfizer. Harrison also keeps his Equal Weight rating and $209 price target on Moderna.